Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating Expenses    
Research and development expenses $ 1,539,070 $ 1,627,480
General and administrative expenses 1,270,528 2,478,055
Operating Loss (2,809,598) (4,105,535)
Other Income (Expense), net 83,217 83,462
Net Loss $ (2,726,381) $ (4,022,073)
Net Loss Per Common Share - Basic $ (1.11) $ (3.53)
Net Loss Per Common Share - Diluted $ (1.11) $ (3.53)
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic 2,466,523 1,138,573
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted 2,466,523 1,138,573